25th week of 2009 patent applcation highlights part 51 |
Patent application number | Title | Published |
20090156489 | PROMOTION OF AXONAL REGENERATION - The present invention concerns a method of promoting axonal regeneration. In particular, the invention concerns a method of promoting the growth or regeneration of neurons, and treating disease or conditions associated with the loss, loss of function or dysfunction of nerve cells, in particular thalamic nerve cells, by administering a polypeptide having a high degree of sequence identity with a native sequence Netrin G1 (NGL-1) or an agonist thereof. | 2009-06-18 |
20090156490 | PEPTIDES FOR DIAGNOSTIC AND THERAPEUTIC METHODS FOR CELIAC SPRUE - Detection of toxic gluten oligopeptides refractory to digestion and antibodies and T cells responsive thereto can be used to diagnose Celiac Sprue. Analogs of such oligopeptides are useful in the inhibition of immune responses. | 2009-06-18 |
20090156491 | METHODS OF INHIBITING ANGIOGENESIS WITH FRAGMENTS AND HOMOLOGS OF TROPONIN SUBUNIT I - The present invention relates to methods of inhibiting angiogenesis associated with a disease or disorder with peptides homolgous to amino acid residues 130-137 or 132-139 of human troponin subunit I. | 2009-06-18 |
20090156492 | Methods of Using IL-1 Antagonists to Treat Autoinflammatory Disease - Methods of treating, inhibiting, or ameliorating an autoinflammatory disorder, disease, or condition in a subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein the autoinflammatory disorder, disease, or condition is treated, inhibited, or ameliorated. The IL-1 antagonist is an IL-1 trap, preferably comprising a sequence selected from the group consisting of SEQ ID NO: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, or a substantially identical having at least 95% identity to the sequence shown in SEQ ID NO: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 and capable of binding and inhibiting IL-1. The therapeutic methods are useful for treating a human adult or child suffering from Neonatal Onset Multisystem Inflammatory Disorder (NOMID/CINCA), Muckle-Wells Syndrome (MWS), Familial Cold Autoinflammatory Syndrome (FCAS), familial mediterranean fever (FMF), or systemic onset juvenile rheumatoid arthritis (Still's Disease). | 2009-06-18 |
20090156493 | UROCORTIN-III AND USES THEREOF - A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2α or β. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to be identified receptor. | 2009-06-18 |
20090156494 | COMPOSITIONS AND METHODS COMPRISING GASTRIN COMPOUNDS - The invention relates generally to novel compositions and methods comprising a gastrin compound. The compositions and methods provide beneficial effects, in particular sustained beneficial effects, in the treatment of diabetes. | 2009-06-18 |
20090156495 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES - The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is expressed on T cells. The present invention also provides the discovery of zB7R1's ability to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided. | 2009-06-18 |
20090156496 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING PERIPHERAL NERVE DAMAGE - Disclosed herein is a method for treating and/or preventing peripheral nerve damage in a subject comprising administering to the subject a therapeutically effective amount of oncomodulin. Preferably, the subject is a mammal, most preferably, a human. In preferred embodiments, the oncomodulin may be used in combination with mannose, a mannose derivative and/or inosine. | 2009-06-18 |
20090156498 | FUSION PROTEINS FOR DELIVERY OF GDNF TO THE CNS - The invention provides compositions, methods, and kits for increasing transport of GDNF across the blood brain barrier while allowing its activity to remain substantially intact. The GDNF is transported across the blood brain barrier via one or more endogenous receptor-mediated transport systems. | 2009-06-18 |
20090156499 | Antimicrobial Peptides and Methods of Identifying the Same - Antimicrobial peptides and methods of identifying the same are provided. | 2009-06-18 |
20090156500 | NEUREGULINS FOR PREVENTION AND TREATMENT OF DAMAGE FROM ACUTE ASSAULT ON VASCULAR AND NEURONAL TISSUE AND AS REGULATORS OF NEURONAL STEM CELL MIGRATION - Neuregulin, a known neuroprotein, has been found to ameliorate or prevent damage caused by mechanical or chemical assault to blood vessels and, when administered into the cerebral spinal fluid, can ameliorate damage to neuronal tissue caused by stroke or inflammation. Additionally, neuregulin has been found to be useful for enhancement of stem cell migration from the ventricle to the site of injury to the brain. | 2009-06-18 |
20090156501 | IDENTIFICATION OF LIGANDS BY SELECTIVE AMPLIFICATION OF CELLS TRANSFECTED WITH RECEPTORS - The invention is directed to a method for identifying substances acting as ligands for transfected receptors by using transfected markers to measure receptor/ligand interactions. The present invention also relates to a method of identifying compounds which act as inverse agonists of the 5-HT2A receptor, the method comprising contacting a constitutively active 5-HT2A receptor with at least one test compound and determining any decrease in the amount of basal activity of the receptor so as to identify a test compound which is an inverse agonist of the 5-HT2A receptor. Such inverse agonists may be used in the treatment of schizophrenia and related psychoses. | 2009-06-18 |
20090156502 | DIPHTHERIA TOXIN VARIANT - The present invention relates to methods and compositions of modified variants of diphtheria toxin (DT) that reduce binding to vascular endothelium or vascular endothelial cells, and therefore, reduce the incidence of Vascular Leak Syndrome. One aspect of the present invention relates to a polypeptide toxophore from a modified DT, wherein the mutation is the substitution or deletion at least one amino acid residue at the amino acid residues 6-8, 28-30 or 289-291 of native DT. Another aspect of the present invention relates to a fusion protein which comprises a modified DT and a non-DT fragment. Another aspect of the present invention relates to the use of modified DT for the treatment of cancer. | 2009-06-18 |
20090156503 | CELL PENETRATING PEPTIDES FOR INTRACELLULAR DELIVERY OF MOLECULES - The present invention concerns cell-penetrating peptides which comprise an amino acid sequence consisting of GLX | 2009-06-18 |
20090156504 | METHODS OF TREATING BLOOD CELL DEPLETION - Provided herein are methods and compositions useful for the replenishment of blood cells in a mammal after exposure to therapeutic radiation or drugs. Radiation illness can be reduced in animals by treatment with substance P analogs. In one embodiment, granulocytes can be regenerated after therapeutic radiation by the administration of a substance P analog. In one embodiment, substance P analogs are useful for reducing PARP activity or PARP expression. In one embodiment, substance P analogs are useful for preventing, reducing or ameliorating adverse effects of drugs. In one embodiment, drug induced blood dyscrasias can be ameliorated by the methods and compositions provided herein. | 2009-06-18 |
20090156505 | SELF-ASSEMBLY AND MINERALIZATION OF PEPTIDE-AMPHIPHILE NANOFIBERS - Peptide-amphiphilic compositions capable of self-assembly into useful nanostructures. | 2009-06-18 |
20090156506 | USE OF VEGF-D IN THE DIAGNOSIS OF LYMPHANGIOLEIOMYOMATOSIS (LAM) DISEASE - Described herein are methods of diagnosing lymphangioleiomyomatosis (LAM) that permits differentiating LAM from another lung disorder. Methods of treatment are also provided. | 2009-06-18 |
20090156507 | Cell permeable conjugates of peptides for inhibition of protein kinases - The present invention provides inhibitors of protein kinases comprising a molecule having at least a first moiety competent for penetration of the molecule into cells, and a second moiety for having a protein kinase inhibiting effect within the cells. The first moiety is joined to the second moiety through a linker or a spacer. The complex molecules are preferably peptide conjugates having improved cell-permeability, serum stability and kinase selectivity compared to known protein kinase inhibitors. Pharmaceutical compositions that include these protein kinase inhibitors, and methods of using such compositions for treatment of cancers and other diseases associated with protein kinase activity are also disclosed. | 2009-06-18 |
20090156508 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF - The invention relates to synthetic peptide amides that are ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P | 2009-06-18 |
20090156509 | Tri-peptide Inhibitors of Serine Elastases - The present invention provides compounds of formula (I): | 2009-06-18 |
20090156510 | USE OF NOTCH SIGNALING REGULATORS FOR MODULATING OSTEOGENESIS - The present invention provides methods of treating osteoporosis and other bone disorders by inhibiting Notch signaling. | 2009-06-18 |
20090156511 | Agent for Enhancing Antiseptic Power - The present invention relates to a preservative efficacy-enhancing agent capable of allowing an antiseptic agent to exhibit a high preservative efficacy even when the antiseptic agent is used at a low concentration; a preservative efficacy-enhancing composition containing the same; and a method for enhancing a preservative efficacy of antiseptic agents. The present invention relates to: (1) a preservative efficacy-enhancing agent for antiseptic agents which includes an amphiphilic galactose derivative (A) as an effective ingredient; (2) a preservative efficacy-enhancing composition including 0.01 to 30% by mass of an amphiphilic galactose derivative (A) and 0.01 to 1.0% by mass of an antiseptic agent (B); and (3) a method for enhancing a preservative efficacy of an antiseptic composition which includes the step of allowing 0.01 to 30% by mass of an amphiphilic galactose derivative (A) to coexist with an antiseptic agent (B) in the composition. | 2009-06-18 |
20090156512 | Lincomycin Derivatives and Antimicrobial Agents Comprising the Same as Active Ingredient - This invention provides compounds of formula (I) or its pharmacologically acceptable salt or solvate, wherein A represents aryl or a monocyclic or bicyclic heterocyclic group, R | 2009-06-18 |
20090156513 | JUCARA AND ACAI FRUIT-BASED DIETARY SUPPLEMENTS - The present disclosure relates to stable, palatable, freeze-dried, fruit-based dietary supplements. In one embodiment, the disclosures relates to compositions of Açai fruit and Jucara fruit with high antioxidant capability and cyclooxygenase-inhibitory activity, and their uses. The disclosure further provides for methods of making stable, palatable, freeze-dried, fruit-based dietary supplements from Açai fruit and Jucara fruit. | 2009-06-18 |
20090156514 | NOVEL MACROLACTAM COMPOUNDS - The invention relates generally to novel macrolactams and their analogs, to processes for the preparation of these novel macrolactams, to pharmaceutical compositions comprising the novel macrolactams; and to methods of using the novel macrolactams to treat or inhibit various disorders. | 2009-06-18 |
20090156515 | COMPOSITION COMPRISING TRITERPENE SAPONINS AND COMPOUNDS WITH ANGELOYL FUNCTIONAL GROUP, METHODS FOR PREPARING SAME AND USES THEREOF - This invention provides composition comprising a triterpenoidal saponin, triterpenoid, triterpenoidal compound or sapongenin, comprising at least two side groups selected from the group consisting of: angeloyl groups, tigloyl groups and senecioyl groups, wherein the side groups are attached to carbon 21, 22 or/and 28 of triterpenoidal saponin, triterpenoid, triterpenoidal compound or sapongenin backbone. This invention provides a composition for inhibiting tumor cell growth, comprising an appropriate amount of a triterpenoidal saponin, triterpenoid, triterpenoidal compound or sapongenin, wherein the triterpenoidal saponin, triterpenoid, triterpenoidal compound or sapongenin comprises any two side groups selected from the group consisting of: angeloyl groups, tigloyl groups and senecioyl groups, wherein the side groups are attached to carbon 21, 22 or/and 28 of triterpenoidal saponin, triterpenoid, triterpenoidal compound or sapongenin backbone. | 2009-06-18 |
20090156516 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE - Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition. | 2009-06-18 |
20090156517 | STABLE PHARMACEUTICAL COMPOSITIONS OF AMINOGLYCOSIDE ANTIBIOTICS, ION-CHELATING AGENTS, AND BUFFERS - A pharmaceutical composition comprising: at least one aminoglycoside antibiotic and (a) at least one ion chelating agent used for inhibiting particulate formation, or (b) at least one buffer, or (c) at least one ion chelating agents and at least one buffer simultaneously. The composition for use in controlling microbial infection can be formulated into a solution, or combined with at least one beta-lactam antibiotic, or combined with at least one of beta-lactam antibiotic and at least one beta-lactamase inhibitor into a solution in a container. | 2009-06-18 |
20090156518 | STABLE PHARMACEUTICAL COMPOSITION COMPRISING BETA-LACTAM ANTIBIOTIC AND BUFFER - A pharmaceutical composition, comprising: at least one β-lactam antibiotic and at least one buffer component; wherein when the pharmaceutical composition is used as an anti-microbial drug, it optionally comprises further at least one aminoglycoside antibiotic mixed with the β-lactam antibiotic and the buffer component. | 2009-06-18 |
20090156519 | Modified KSA and Uses Thereof - The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer. | 2009-06-18 |
20090156520 | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA - Introduction of double stranded RNA into cells, cell culture, organs and tissues, and whole organisms, particularly vertebrates, specifically attenuates gene expression. | 2009-06-18 |
20090156521 | Gpr17 modulators,method of screening and uses thereof - The invention provides GPR17 modulators, methods of screening and use thereof for diagnosis and therapy of diseases or dysfunctions involving GPR17 activation, particularly ischemic brain damage. | 2009-06-18 |
20090156522 | Pancreatic Cancer Genes - The present invention provides the art with the DNA coding sequences of polynucleotides that are up-or-down-regulated in cancer and dysplasia. These polynucleotides and encoded proteins or polypeptides can be used in the diagnosis or identification of cancer and dysplasia. Inhibitors of the up-regulated polynucleotides and proteins can decrease the abnormality of cancer and dysplasia. Enhancing the expression of down-regulated polynucleotides or introducing down-regulated proteins to cells can decrease the growth and/or abnormal characteristics of cancer and dysplasia. | 2009-06-18 |
20090156523 | METHODS AND COMPOSITIONS FOR MODULATING FOXO1 ACTIVITY AND INSULIN SIGNALING - The invention provides methods for modulating insulin signaling pathway and methods for treating insulin resistance. The methods employ agents which modulate FOXO1 subcellular localization. The invention also provides methods of screening for compounds that modulate insulin signaling related activities such as gluconeogenesis and cell proliferation. | 2009-06-18 |
20090156524 | Novel siRNAS and methods of use thereof - The invention relates to compounds, in particular siRNAs, which inhibit the expression of specific human genes. The invention also relates to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The present invention also provides a method of treating and/or preventing the incidence or severity of various diseases or conditions associated with the genes and/or symptoms associated with such diseases or conditions comprising administering to a subject in need of treatment for such disease or condition and/or symptom the compound or the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the subject. The invention also provides antibodies which inhibit specified human polypeptides and pharmaceutical compositions comprising one or more such antibodies. | 2009-06-18 |
20090156525 | Low-Density Lipoprotein Receptor-Related Protein 2 Clears Amyloid-Beta Peptide A cross the Blood-Brain Barrier via Apolipoprotein J - Low-density lipoprotein receptor-related protein 2 (LRP2) is a potential receptor to regulate the level of apolipoprotein J (apoJ) in the central nervous system, which is the major carrier of amyloid-β peptide (Aβ). ApoJ is cleared from brain interstitial fluid (ISF) and cerebrospinal fluid (CSF) by LRP2-mediated transcytosis across epithelial and endothelial barriers. At physiological ISF/CSF levels, apoJ is rapidly transported by LRP2 across the blood-brain barrier (BBB). Importantly, apoJ also substantially enhances clearance from the brain of amyloidogenic Aβ isoforms (i.e., higher β-sheet content such as Aβ42) as apoJ-Aβ by LRP2-mediated transport. | 2009-06-18 |
20090156526 | COMPOSITIONS AND METHODS FOR MODULATION OF LMNA EXPRESSION - Disclosed herein are compounds, compositions and methods for modulating the expression of LMNA in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Further provided are methods of identifying cis splicing regulatory elements of a selected mRNA using the disclosed compounds. | 2009-06-18 |
20090156527 | ANTIVIRAL OLIGONUCLEOTIDES TARGETING VIRAL FAMILIES - Random sequence oligonucleotides that have antiviral activity are described, along with their use as antiviral agents. In many cases, the oligonucleotides are greater than 40 nucleotides in length. Also described are methods for the prophylaxis or treatment of a viral infection in a human or animal, and a method for the prophylaxis treatment of cancer caused by oncoviruses in a human or animal. The methods typically involve administering to a human or animal in need of such treatment, a pharmacologically acceptable, therapeutically effective amount of at least oligonucleotide that does not act by a sequence complementary mode of action. | 2009-06-18 |
20090156528 | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS C VIRUS (HCV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) - The present invention concerns methods and reagents useful in modulating hepatitis C virus (HCV) gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against hepatitis C virus (HCV) gene expression and/or activity. The small nucleic acid molecules are useful in the treatment and diagnosis of HCV infection, liver failure, hepatocellular carcinoma, cirrhosis and any other disease or condition that responds to modulation of HCV expression or activity. | 2009-06-18 |
20090156529 | RNAi Inhibition of Alpha-ENaC Expression - The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides. | 2009-06-18 |
20090156530 | Norepinepherine Transporter Mutants and Uses Thereof - The present invention provides norepinepherine transporter (NET) mutants which display altered phosphorylation at site T30 and altered receptor trafficking. Methods for the use of the NET mutants, e.g., screening of compounds which alter NET trafficking, are also provided. A transgenic animal such as a mouse may comprise a NET mutant of the present invention. | 2009-06-18 |
20090156531 | Use of Inhibitors of Scinderin and/or Ephrin-A1 for Treating Tumors - The invention relates to the use of inhibitors of the expression or the activity of scinderin and/or of ephrin-A1 inhibitors for increasing the susceptibility of tumor cells to CTL killing. Such inhibitors may be for instance interfering RNAs targeting the scinderin gene and/or interfering RNAs targeting the ephrin-A1 gene. | 2009-06-18 |
20090156532 | SNP BINDING SITE FOR microRNAs IN HLA-G - Analysis of microRNA interference with HLA-G expression identified the HLA-G 3′UTR SNP+3142G/C that disrupts a target for microRNA 148 (miR148) and is associated with asthma. The polymorphism is associated with protection from (or susceptibility to) moderate to severe viral infection in the first 3 years of life and asthma by age 6, with an interaction with mother's affection status (asthma). A SNP in the 3′-Untranslated Region (UTR) of HLA-G influences the targeting of 3 micro(mi)RNAs to the gene. Allele-specific targeting of these miRNAs accounts, at least in part, for the association between HLA-G and the risk of asthma. | 2009-06-18 |
20090156533 | RNA INTERFERENCE MEDIATED INHIBITION OF STROMAL CELL-DERIVED FACTOR-1 (SDF-1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) - The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of stromal cell-derived factor-1 (SDF-1) gene expression and/or activity. The present invention is also directed to compounds, compositions, and methods relating to traits, diseases and conditions that respond to the modulation of expression and/or activity of genes involved in SDF-1 gene expression pathways or other cellular processes that mediate the maintenance or development of such traits, diseases and conditions. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating or that mediate RNA interference (RNAi) against SDF-1 gene expression. Such small nucleic acid molecules are useful, for example, in providing compositions for treatment of traits, diseases and conditions that can respond to modulation of SDF-1 expression in a subject, such as ocular disease, cancer and proliferative diseases and any other disease, condition, trait or indication that can respond to the level of SDF-1 in a cell or tissue. | 2009-06-18 |
20090156534 | GLOBIN LENTIVIRAL VECTORS FOR TREATMENT OF DISEASE - The invention provides compositions and methods for the treatment or prevention of disease, including, for example, β-thalassemia, anemias (e.g., sickle cell anemia) and other hemoglobinopathologies. | 2009-06-18 |
20090156535 | MicroRNAs for Modulating Herpes Virus Gene Expression - An algorithm for identification of microRNA (miRNA) targets within viral and cellular RNA is disclosed. Also disclosed are essential herpes virus genes whose transcripts contain one or more targets of miRNAs encoded by herpes viruses or by host cells as predicted by the algorithm, and the use of such targets, miRNAs and their derivatives for modulating viral replication and latency. | 2009-06-18 |
20090156536 | AIMP2-DX2 Gene and SiRNA Targeting AIMP2-DX2 - The present invention relates to a variant of AIMP2 lacking exon 2 gene, named as AIMP2-DX2 gene, which is specifically expressed in cancer cells. The AIMP2-DX2 gene and siRNA targeting AIMP2-DX2 can be successfully used in the development of diagnosis and treatment of cancer. | 2009-06-18 |
20090156537 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING ASTHMA OR OTHER ALLERGIC OR INFLAMMATORY DISEASES - The present invention provides compositions and methods useful for detecting or treating asthma or other allergic or inflammatory diseases. In one aspect, the methods of the present invention include inhibiting the activity or expression of a component of an arginine metabolic pathway in tissues affected by asthma or other allergic or inflammatory diseases. In many embodiments, the component being inhibited is a cationic amino acid transporter, an arginase, or a component downstream of the arginase. In many other embodiments, the activity or expression of the component is inhibited by an agent that binds to the component. In still many other embodiments, the activity or expression of the component is inhibited by an agent that binds a polynucleotide encoding the component. | 2009-06-18 |
20090156538 | MODULATION OF ENDOTHELIAL LIPASE EXPRESSION - Compounds, compositions and methods are provided for modulating the expression of endothelial lipase. The compositions comprise oligonucleotides, targeted to nucleic acid encoding endothelial lipase. Methods of using these compounds for modulation of endothelial lipase expression and for diagnosis and treatment of disease associated with expression of endothelial lipase are provided. | 2009-06-18 |
20090156539 | ANTISENSE OLIGONUCLEOTIDES (ODN) AGAINST SMAD7 AND USES THEREOF IN MEDICAL FIELD - The invention relates to antisense oligonucleotidic sequences (ODN) against Smad7 suitably modified, and their uses in medical field as therapeutic biological agents, in particular in the treatment of chronic inflammatory bowel disease, such as Crohn's disease and ulcerative colitis. | 2009-06-18 |
20090156540 | METHOD FOR DIAGNOSING AND/OR PREDICTING THE DEVELOPMENT OF AN ALLERGIC DISORDER AND AGENTS FOR TREATING AND/OR PREVENTING SAME - The present invention relates to genes whose level of expression is different in allergic animals compared with non-allergic animals. In particular, the present invention relates to a method for predicting the development of an allergic disorder in a mammal by determining the gene expression pattern of a panel of specific sequences comprising CAMK2D and CDH1 within a nucleic acid pool that have been predetermined to either increase or decrease in response to allergy. | 2009-06-18 |
20090156541 | DBAIT AND USES THEREOF - The invention relates to compositions and methods for interfering with the DNA repair of double strand breaks (DSBs). The invention discloses novel double-stranded nucleic acid molecules. that act as baits and hijack the holocomplex of enzymes responsible of DNA DSB sensing, signaling and/or repair pathways, in particular the non homologous end joining (NHEJ) pathway of DSB repair. | 2009-06-18 |
20090156542 | MCP-1 Binding Nucleic Acids And Use Thereof - The present invention is related to a nucleic acid molecule capable of binding to MCP-1, whereby the nucleic acid molecule is for use as a medicament for the treatment and/or prevention of a chronic disease or chronic disorder, preferably selected from the group consisting of chronic respiratory disease, chronic kidney disease and systemic lupus erythematosus. | 2009-06-18 |
20090156543 | METHODS AND COMPOSITIONS RELATING TO EXPRESSION FACTORS - The invention describes an expression factor and methods for inhibiting the growth of cells, for enhancing the activity of a drug, and for inhibiting the virulence of microbes. Methods of screening for expression factor inhibitors are also described. The compositions comprise at least one expression factor inhibitor and may further comprise at least one drug. | 2009-06-18 |
20090156544 | A1 ADENOSINE RECEPTOR AGONISTS - Disclosed are novel compounds that are partial and full A | 2009-06-18 |
20090156545 | Substituted Phosphate Esters of Nucleoside Phosphonates - Compounds and compositions are provided for treatment, prevention, or amelioration of a variety of medical disorders associated with viral infections and/or cell proliferation. The compounds provided herein are obtained by attaching the phosphonate nucleoside of interest to alkyloxyalkyl-phosphate or alkyl-phosphate in a phosphate-phosphono anhydride linkage to provide a modified nucleoside phosphonate drug. | 2009-06-18 |
20090156546 | Compositions and methods for modulating the immune system - The present invention provides methods and compositions for the prophylaxis of blood cell disorders such as neutropenia, thrombocytopenia, lymphocytopenia, and anaemia. The invention provides methods wherein compositions comprising at least one cytokinin compound are administered either therapeutically or prophylactically. The invention further has utility in methods of DNA repair. | 2009-06-18 |
20090156547 | AMIDE PRODRUG OF GEMCITABINE, COMPOSITIONS AND USE THEREOF - The present invention relates to novel amide prodrugs of gemcitabine, compositions thereof and methods for using. | 2009-06-18 |
20090156548 | FLUOROCYTIDINE DERIVATIVES AND COX-2 INHIBITORS FOR THE TREATMENT OF CANCER - The present invention provides, in certain embodiments, methods for the treatment of colorectal cancer comprising administering a COX-2 inhibitor and fluorocytidine derivative to a human patient. In certain embodiments, a radiation therapy is also administered to the patient. | 2009-06-18 |
20090156550 | COMPOSITION CONTAINING OLIGOSACCHARIDES FOR THE TREATMENT/PREVENTION OF INFECTIONS - The present invention relates to the use of oligosaccharide mixtures for the treatment and/or prevention of infections, in particular for reducing the severity of childhood infection or the treatment and/or prevention of childhood infection. | 2009-06-18 |
20090156551 | NOVEL COMPOSITION - The invention relates to novel compositions comprising magnolol and honokiol wherein the mol ratio of magnolol to honokiol is less than 0.6 as well as to the use of these compositions as a medicament, in particular as a medicament for the treatment, co-treatment or prevention of inflammatory disorders. | 2009-06-18 |
20090156552 | TOPICAL DELIVERY OF PHTHALOCYANINES - The invention relates to topical pharmaceutical compositions comprising a phthalocyanine, wherein a diamagnetic metal ion moiety is either coordinated or covalently bound to the phthalocyanine core. The invention also relates to methods for destroying cancer tissue, precancerous cells, photo-aged cells, damaged cells, or otherwise pathologic cells, or activated cells, such as lymphocytes or other cells of the immune system, or activated or inflamed tissue cells comprising topically administering to the cancer tissue or surrounding tissue an effective amount of a phthalocyanine composition. | 2009-06-18 |
20090156553 | PIPERAZINE COMPOUNDS WITH A HERBICIDAL ACTION - The invention relates to the use of piperazine compounds of formula (I) or the agriculturally useful salts of piperazine compounds of formula (I) as herbicides, the variables in formula (I) being defined as cited in the claims and the description. | 2009-06-18 |
20090156554 | P13-KINASES - New compounds of formula 1 are provided which by virtue of their pharmaceutical activity as PI3-kinase modulators may be used in the therapeutic field for the treatment of inflammatory or allergic diseases. | 2009-06-18 |
20090156555 | PYRROLOTRIAZINE ANILINE PRODRUG COMPOUNDS USEFUL AS KINASE INHIBITORS - Compounds having the Formula (I), including pharmaceutically acceptable salts thereof | 2009-06-18 |
20090156556 | AMINOPROPANOL DERIVATIVES - Compounds of formula I: | 2009-06-18 |
20090156557 | KINASE INHIBITORS - Compounds are provided for use with kinases that comprise a compound selected from the group consisting of: | 2009-06-18 |
20090156558 | PHOSPHONATE ANALOGS OF ANTIMETABOLITES - The invention is related to phosphorus substituted antimetabolites, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 2009-06-18 |
20090156559 | 2-ethyl N,N-bis(2-chloroethyl)phosphorodiamidates - 2-{[2-(Substituted amino)ethyl]sulfonyl}ethyl N,N-bis(2-chloroethyl)phosphorodiamidates and their salts, their preparation and intermediates in their preparation, pharmaceutical compositions containing them, and methods of treatment using them. The compounds are useful for treating cancer and autoimmune diseases, alone and in combination with other therapies. | 2009-06-18 |
20090156560 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION - Disclosed herein are compounds that are tissue-nonspecific alkaline phosphatase inhibitors. The disclosed compounds are used to treat, prevent, or abate vascular calcification, arterial calcification and other cardiovascular diseases. | 2009-06-18 |
20090156561 | Use of Cholinesterase Inhibitors In Smoking Cessation - A method of causing a patient to reduce or cease tobacco use that involves the administration of a cholinesterase inhibitor. | 2009-06-18 |
20090156562 | NOVEL COLORED SOLUTIONS OF INJECTABLE DRUGS AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS - The invention is directed to pharmaceutical compositions comprising colored solutions, colored emulsions, or colored powders of injectable pharmaceuticals wherein said pharmaceuticals are selected from the group consisting of muscle relaxants, hypnotics, induction agents, and anticholinergics. The formulations of the present invention may all be colored using fluorescein. Different colors may be achieved by either varying the concentration of fluorescein, or by combining fluorescein with another dye. The invention is also directed to methods involving the use of said pharmaceutical compositions. | 2009-06-18 |
20090156563 | Glucan Compositions - A cosmetic or pharmaceutical composition is provided comprising: a) 0.001 to less than 0.2% by weight, based on the weight of the total composition, of a scleroglucan having a mean molecular weight of 1×10 | 2009-06-18 |
20090156564 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR RELIABLE ACHIEVEMENT OF ACCEPTABLE SERUM TESTOSTERONE LEVELS - Described are methods for providing prolonged physiologically acceptable steady state serum testosterone levels in a patient deficient in endogenous testosterone levels, methods for male contraception and methods for treating a disease or symptom associated with deficient endogenous levels of testosterone in a man, by intramuscularly administering testosterone esters in a vehicle. | 2009-06-18 |
20090156565 | COMPOSITION AND USE THEREOF IN ENHANCING A THERAPEUTIC EFFECT OF AN ANTIEPILEPTIC DRUG - A composition and a method for the use of the composition for enhancing a therapeutic effect of an antiepileptic drug in treating a seizure in a status epilepticus in an animal. A composition includes a glucocorticoid receptor antagonist and an antiepileptic drug, wherein the glucocorticoid receptor antagonist is present in an amount effective to enhance a therapeutic effect of the antiepileptic drug in treating a seizure in a status-epilepticus in an animal. A method of use of a glucocorticoid receptor antagonist for enhancing a therapeutic effect of an antiepileptic drug in treating a seizure in a status epilepticus in an animal, the method includes administering the glucocorticoid receptor antagonist and the antiepileptic drug, wherein the glucocorticoid receptor antagonist is administered to the animal prior to, contemporaneous with, or subsequent to administering the antiepileptic drug in an amount effective to enhance the therapeutic effect of the antiepileptic drug. | 2009-06-18 |
20090156566 | METHOD OF TREATING MIDDLE EAR INFECTIONS - Aqueous suspension formulations containing dexamethasone and ciprofloxacin are disclosed for the treatment of middle ear infections in human patients having an open tympanic membrane. | 2009-06-18 |
20090156567 | NOVEL ANTI-INFLAMMATORY ANDROSTANE DERIVATIVE - According to one aspect of the invention, there is provided a compound of formula (I) | 2009-06-18 |
20090156568 | Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods - Pharmaceutical compositions suitable for administration into the interior of an eye of a person or animal are described. The present compositions include one or more components which are effective in providing a reduced toxicity relative to existing intraocular ophthalmic compositions. The present compositions include one or more therapeutic agents in amounts effective in providing a desired therapeutic effect when placed in an eye, and one or more retinal friendly excipients that have a reduced toxicity relative to benzyl alcohol or polysorbate 80. In certain compositions, the excipient component of the compositions comprises one or more cyclodextrins or cyclodextrin derivatives. Methods of using the compositions to treat ocular conditions are also described. | 2009-06-18 |
20090156569 | ORAL CONTRACEPTIVE SPRAY - The subject invention provides a liquid contraceptive formulation for oral transmucosal administration. The formulation comprises etonogestrel, optionally together with ethinyl estradiol but does not contain a matrix former or a percutaneous absorption promoter, which is a hydroxy acid or a salt thereof. | 2009-06-18 |
20090156570 | Synergistic biocide composition comprising 2-methylisothiazoline-3-one - A biocide composition, comprising 2-methylisothiazolin-3-one as a biocidal active ingredient and at least one further biocidal active ingredient, as an additive to materials capable of being attacked by harmful microorganisms, wherein the composition comprises a pyrithione as the further biocidal active ingredient. | 2009-06-18 |
20090156571 | BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 - The present invention discloses novel compounds of Formula I: possessing 11 β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11 β-HSD type 1 activity. | 2009-06-18 |
20090156572 | Nitrogen-containing heterocyclic compound and use thereof - The present invention relates to a compound represented by the formula | 2009-06-18 |
20090156573 | N-(Aminoheteroaryl)-1H-indole-2-carboxamide derivatives, and preparation and therapeutic application thereof - The invention concerns compounds of general formula (I): | 2009-06-18 |
20090156574 | 2-ACYLAMINO-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF - The invention relates to 2-acylamino-4-phenylthiazole derivatives of general formula (I): | 2009-06-18 |
20090156575 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES - The invention provides compounds of general formula | 2009-06-18 |
20090156576 | Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases - Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. Such compounds are MEK inhibitors and are useful in the treatment of proliferative diseases, such as cancer. Also disclosed are pharmaceutical compositions containing such compounds as well as methods of using the compounds and compositions of the invention in the treatment of cancer. | 2009-06-18 |
20090156577 | 7-AMINO ALKYLIDENYL-HETEROCYCLIC QUINOLONES AND NAPHTHYRIDONES - The present invention relates to compounds having a structure according to Formula (I) | 2009-06-18 |
20090156578 | 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents - In part, the present invention is directed towards compounds with FabI inhibiting properties. Such compounds may also inhibit other enzymes, including those similar to FabI either structurally or functionally, for example, Fab K. Kits and compositions that include the disclosed compounds are also provided. Methods of treating a subject with a bacterial illness is also disclosed. | 2009-06-18 |
20090156579 | Combination of a Dipeptidyl Peptidase-4 Inhibitor and an Anti-Hypertensive Agent for the Treatment of Diabetes and Hypertension - The present invention relates to pharmaceutical compositions comprising a combination of a particular dipeptidyl peptidase-4 (DPP-4) inhibitor and an anti-hypertensive agent selected from the group consisting of an angiotensin II receptor antag-onist and an angiotensin converting enzyme inhibitor, kits containing such combinations and methods of using such compositions for the treatment of diabetes, diabetes-related disorders, hypertension, and hypertension-related disorders. | 2009-06-18 |
20090156580 | ANTI-FOOT-AND-MOUTH DISEASE VIRUS AGENT FOR ANIMAL BELONGING TO FAMILY SUIDAE OR SHEEP, AND METHOD FOR PREVENTION OR TREATMENT OF FOOT-AND-MOUTH DISEASE IN ANIMAL BELONGING TO FAMILY SUIDAE OR SHEEP - Disclosed is an anti-foot-and-mouth disease virus agent for an animal belonging to the Family Suidae, which comprises 3-oxo-3,4-dihyro-2-pyrazincarboxamide or a salt thereof. The agent is extremely useful for the prevention or treatment of food-and-mouth disease in an animal belonging to the Family Suidae. Also disclosed is an anti-foot-and-mouth disease virus agent for sheep, which comprises 3-oxo-3,4-dihyro-2-pyrazincarboxamide or a salt thereof. The agent is extremely useful for the prevention, therapy or the like of food-and-mouth disease in sheep. | 2009-06-18 |
20090156581 | Aminergic pharmaceutical compositions and methods - Pharmaceutical compositions and method using aminergic compounds and complement compounds. Compositions are provided comprising: (a) a subefficacious amount of a non-adrenergic aminergic compound or of an adrenergic antagonist; and (b) a safe and effective amount of a complement compound. Methods are also provided comprising the administration of: (a) a low dose of a non-adrenergic aminergic compound or of any adrenergic antagonist; and (b) a safe and effective amount of a complement compound. Non-adrenergic aminergic compounds can comprise a histaminergic, dopaminergic, muscarinergic, serotoninergic, octopaminergic, or trace aminergic compound. Complement compounds include ascorbates, opioids, polycarboxylic acid chelators, resveratrols, cysteines, substituted derivatives and analogs thereof, and mixtures thereof. Preferred complements include ascorbates, particularly ascorbic acid. Methods include the treatment of: neurological and neural disorders; mood and behavior disorders; cardiac, vascular, and cardiovascular disorders; hypertension, headache; respiratory disorders; gastrointestinal disorders; obesity; asthma, allergy; smooth muscle contraction disorders; nasal or nasopharyngeal conditions; genitourinary disorders; ocular disorders, glaucoma; hormone- or neurotransmitter-release or -secretion disorders. | 2009-06-18 |
20090156582 | Pyrazole Compound - The present invention provides a pyrazole compound represented by the formula (I): | 2009-06-18 |
20090156583 | Tricyclic Amide Derivatives - The present invention relates to compounds of formula I | 2009-06-18 |
20090156584 | IRRADIATED COMPOSITIONS AND TREATMENT OF CANCERS WITH RADIATION IN COMBINATION WITH TAUROLIDINE AND/OR TAURULTAM - A composition formed by subjecting to ionizing radiation a combination containing a radiation-protective amount of PVP along with a solution, gel or adhesive including taurolidine, taurultam or a mixture thereof; or an aggregate including collagen-free crystals of taurolidine, taurultam or a mixture thereof. | 2009-06-18 |
20090156585 | ORGANIC COMPOUNDS - A specific combination, linked pro-drug or a compound of an angiotensin receptor antagonist and a NEPi are used in the treatment of hypertension. | 2009-06-18 |
20090156586 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS - This invention relates to compounds of the Formula (I): | 2009-06-18 |
20090156587 | Eye Medication Formulation with Antibacterial Agent - A formulation for administration to the eye has at least one pharmaceutical agent such as a mydriatic agent, a cycloplegic agent, an anesthetic or a non-steroidal anti-inflammation agent combined with an anti-bacterial agent and a suitable carrier. The formulation can be made for topical or intracameral administration to the eye. | 2009-06-18 |
20090156588 | 3,4-DIHYDRO-BENZO[E][1,3]OXAZIN-2-ONES - The present invention relates 3,4-dihydro-benzo[e][1,3]oxazin-2-ones which are substituted at the nitrogen atom by unsubstituted or substituted (C | 2009-06-18 |
20090156589 | 1,2-DI(CYCLIC GROUP)SUBSTITUTED BENZENE DERIVATIVE - A compound represented by the following general formula (1) or (100), a salt thereof or a hydrate of the foregoing has excellent cell adhesion inhibitory action and cell infiltration inhibitory action. | 2009-06-18 |
20090156590 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process for Making Them, and Use Thereof for Treating Pain and Other Conditions - Vanilloid receptor ligand compounds corresponding to formula I: | 2009-06-18 |